Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

نویسندگان

Kirsten Fischer

Othman Al-Sawaf

Anna-Maria Fink

Mark Dixon

Jasmin Bahlo

Simon Warburton

Thomas J Kipps

Robert Weinkove

Sue Robinson

Till Seiler

Stephen Opat

Carolyn Owen

Javier López

Kathryn Humphrey

Rod Humerickhouse

Eugen Tausch

Lukas Frenzel

Barbara Eichhorst

Clemens-M Wendtner

Stephan Stilgenbauer

Anton W Langerak

Jacque J M van Dongen

Sebastian Böttcher

Matthias Ritgen

Valentin Goede

Mehrdad Mobasher

Michael Hallek

چکیده

Kirsten Fischer, Othman Al-Sawaf, Anna-Maria Fink, Mark Dixon, Jasmin Bahlo, Simon Warburton, Thomas J. Kipps, Robert Weinkove, Sue Robinson, Till Seiler, Stephen Opat, Carolyn Owen, Javier López, Kathryn Humphrey, Rod Humerickhouse, Eugen Tausch, Lukas Frenzel, Barbara Eichhorst, Clemens-M. Wendtner, Stephan Stilgenbauer, Anton W. Langerak, Jacque J.M. van Dongen, Sebastian Boettcher, Matthias Ritgen, Valentin Goede, Mehrdad Mobasher, and Michael Hallek

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Venetoclax is the first BCL2 inhibitor to enter routine clinical practice. It is an orally bioavailable small molecule that binds BCL2 very specifically. Acting as a pharmacologic mimic of the proteins that initiate apoptosis (a so-called BH3 mimetic), venetoclax rapidly induces apoptosis in chronic lymphocytic leukemia (CLL) cells, which express high levels of BCL2 and rely on it to maintain t...

متن کامل

Venetoclax Yields Strong Responses in CLL.

Results from an international phase II study show that the investigational BCL2 inhibitor venetoclax is effective in patients with chronic lymphocytic leukemia and the chromosome 17p deletion, whose prognosis is particularly poor. Venetoclax yielded high and durable responses in this population, including several complete remissions.

متن کامل

A BH3 Mimetic for Killing Cancer Cells

Venetoclax is a BH3 mimetic approved for treating chronic lymphocytic leukemia. Cancer cells are resistant to apoptosis but "primed for death" by elevated BCL-2, which binds to pro-apoptotic proteins and holds them in check. Venetoclax releases this antagonism and is the first approved drug to target a protein-protein interaction.

متن کامل

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia

The introduction of targeted therapy against CD20(+) with the monoclonal antibody rituximab has dramatically improved the survival of B-cell non-Hodgkin lymphoma including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Unfortunately, CLL remains incurable with chemoimmunotherapy, with many patients having refractory or relapsing disease after rituximab-containing therapy. Obinut...

متن کامل